EACA作为一种溶纤维蛋白酶抑制剂用作预防蛛网膜下腔出血(SAH)后的再出血已达十年以上,其作用是抑制胞浆素原合成为胞浆素。由于怀疑其效果且有不良付作用,故系统使用受到一定限制,其中熟知的付作用。如血栓栓塞并发症,其它付作用如怀死性肌病却很少被认识。 EACA, a fibrinolytic inhibitor, has been used for more than 10 years as a re-bleeding after subarachnoid hemorrhage (SAH) to inhibit the synthesis of plasminogen into plasma. Due to the suspicion of its effect and its adverse pay, the use of the system is subject to certain limitations, of which the well-known payoffs apply. Such as thromboembolic complications, other pay role such as wicking myopathy is rarely recognized.